Evidence map›Paper›PMID 30863052›Full record

ArticleInternational journal of nanomedicine2019

Long-term biocompatibility of fluorescent diamonds-(NV)-Z~800 nm in rats: survival, morbidity, histopathology, particle distribution and excretion studies (part IV).

Frank C Barone, Cezary Marcinkiewicz, Jie Li, Yi Feng, Mark Sternberg, Peter I Lelkes, David Rosenbaum-Halevi, Jonathan A Gerstenhaber, Giora Z Feuerstein

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Frank C BaroneSUNY Downstate Medical Center, Department of Neurology, Brooklyn, NY, USA.
Cezary MarcinkiewiczDebina Diagnostic Inc., Newtown Square, PA, USA, cmarcink@temple.edu.
Jie LiSUNY Downstate Medical Center, Department of Neurology, Brooklyn, NY, USA.
Yi FengWuXi AppTec (Suzhou) Co., Ltd., China.
Mark SternbergDebina Diagnostic Inc., Newtown Square, PA, USA, cmarcink@temple.edu.
Peter I LelkesDepartment of Bioengineering, Temple University, College of Engineering, Philadelphia, PA, USA, cmarcink@temple.edu.
David Rosenbaum-HaleviTexas University Health Center, TMC, Houston, TX, USA.
Jonathan A GerstenhaberDepartment of Bioengineering, Temple University, College of Engineering, Philadelphia, PA, USA, cmarcink@temple.edu.
Giora Z FeuersteinDebina Diagnostic Inc., Newtown Square, PA, USA, cmarcink@temple.edu.
Temple University · USSUNY Downstate Health Sciences University · USWuXi AppTec (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThromboembolic events are a major cause of heart attacks and strokes. However, diagnosis of the location of high risk vascular clots is hampered by lack of proper technologies for their detection. We recently reported on bio-engineered fluorescent diamond-(NV)-Z~800nm (FNDP-(NV)) conjugated with bitistatin (Bit) and proven its ability to identify iatrogenic blood clots in the rat carotid artery in vivo by Near Infra-Red (NIR) monitored by In Vivo Imaging System (IVIS). PURPOSE: The objective of the present research was to assess the in vivo biocompatibility of FNDP-(NV)-Z~800nm infused intravenously to rats. Multiple biological variables were assessed along this 12 week study commissioned in anticipation of regulatory requirements for a long-term safety assessment.

methodsRats were infused under anesthesia with aforementioned dose of the FNDP-(NV), while equal number of animals served as control (vehicle treated). Over the 12 week observation period rats were tested for thriving, motor, sensory and cognitive functions. At the termination of study, blood samples were obtained under anesthesia for comprehensive hematology and biochemical assays. Furthermore, 6 whole organs (liver, spleen, brain, heart, lung and kidney) were collected and examined ex vivo for FNDP-NV) via NIR monitored by IVIS and histochemical inspection.

resultsAll animals survived, thrived (no change in body and organ growth). Neuro-behavioral functions remain intact. Hematology and biochemistry (including liver and kidney functions) were normal. Preferential FNDP-(NV) distribution identified the liver as the main long-term repository. Certified pathology reports indicated no outstanding of finding in all organs.

conclusionThe present study suggests outstanding biocompatibility of FNDP-(NV)-Z~800nm after long-term exposure in the rat.

Indexed as

Organ SpecificityParticle SizeAnimalsBehavior, AnimalBiocompatible MaterialsBioengineeringBody WeightFecesFluorescenceMaleNanodiamondsOrgan SizePeptidesRats, Sprague-DawleySnake VenomsSolubilityBiocompatible MaterialsbitistatinNanodiamondsPeptidesSnake Venomsbiocompatibilityex vivo IR organ imagingliver toxicologynanocarbon particles

Identifiers

PMID30863052
PMCPMC6391148
OpenAlexW2914049954

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.